Plans announced for Ph 2 trial of stenoparib + temozolomide for the treatment of recurrent SCLC March 11, 2025
Independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing Ph 1/2a study TUMORAD-01 of 177Lu-SN201 March 11, 2025
Enrollment Completed in Ph 2 Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China March 11, 2025
Clinical Trial Application Submitted in Australia for CS5001 in Combination with 1L SOC for DLBCL March 11, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
First Dose Cohort in STARLIGHT-1 Trial Completed and Approval Received to Initiate Higher Dose Cohort March 4, 2025
First Patient Dosed in the WIN-B Trial of Debio 0123 & Trodelvy® in Advanced Breast Cancer March 3, 2025
Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced February 28, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
First Patients Enrolled in FORTIFI-HN01, Ph 2/3 Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma February 17, 2025
Ph 3 waveLINE-010 Trial of Zilovertamab Vedotin for the Treatment of 1L DLBCL Patients initiated February 11, 2025
First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 February 11, 2025
